# OnCo record paper-imvigor011-nejm-2025 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-imvigor011-nejm-2025/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-imvigor011-nejm-2025" ;
  schema:name "IMvigor011: using a blood test for leftover cancer to decide who gets immunotherapy after bladder surgery"@en ;
  schema:description "Patients whose blood turned positive for tumour DNA after cystectomy lived longer with atezolizumab than placebo; patients who stayed ctDNA-negative did well without any treatment. It is the first ctDNA-guided adjuvant trial to improve survival."@en ;
  schema:url <https://onco.cc/key-papers/paper-imvigor011-nejm-2025/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04660344>, <https://pubmed.ncbi.nlm.nih.gov/?term=IMvigor011%20atezolizumab%20ctDNA%20Powles> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa2511885> ;
  schema:datePublished "2025"^^xsd:gYear ;
  schema:author "Powles T, Chang Y-H, Yamamoto Y, et al." ;
  onco:related <https://onco.cc/pairings/ctdna-mrd-to-adjuvant/>, <https://onco.cc/ideas/idea-ctdna-switch-generalised/>, <https://onco.cc/ideas/idea-bio2-mrd-coverage-with-evidence/> ;
  onco:cancers <https://onco.cc/cancers/urothelial/> ;
  onco:sections <https://onco.cc/fronts/diagnostics/>, <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/mrd-testing/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pdl1/> ;
  onco:drugs <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/signatera/> ;
  onco:terms <https://onco.cc/terms/mrd/>, <https://onco.cc/terms/ctdna/>, <https://onco.cc/terms/neoadjuvant-adjuvant/> ;
  onco:trials <https://onco.cc/trials/imvigor011/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-dormancy-mrd/>, <https://onco.cc/bottlenecks/b-trial-design/>, <https://onco.cc/bottlenecks/b-biomarker-validation/> ;
  onco:journals <https://onco.cc/journals/nejm/> .